MMP9 and glioblastoma: Circulating MMP9 is released by glioblastoma-infiltrating neutrophils, suggesting that antiangiogenic resistance could be related to a specific immunological glioblastoma profile, thus opening new perspectives in the development of therapy for glioblastoma.